TCR2 Therapeutics

$3.66 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About TCR2 Therapeutics

TCR2 Therapeutics, Inc. is an immunotherapy company, which is developing novel T cell therapies for patients suffering from cancer. The Company’s T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing the entire T cell receptor (TCR) signaling complex. The Company has demonstrated anti-tumor activity of TRuC-T cells in preclinical models across various tumor targets. The Company has also developed combinations of TRuC variants with elements designed to sustain the immunotherapeutic response and counteract the immunosuppressive tumor microenvironment. Its platform is highlighted with multiple programs of product candidate, which include TC-210, TC-220, TC-410, TC-110 and TC-310.

Stock Analysis

last close $3.74
1-mo return 11.6%
3-mo return 59.1%
avg daily vol. 229.62T
52-week high 19.03
52-week low 2.07
market cap. $143M
forward pe -
annual div. -
roe -41.3%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 69.5%

Subscribe now for daily local and international financial news